Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Editas Medicine
(NQ:
EDIT
)
5.000
-0.140 (-2.72%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Editas Medicine
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Editas Medicine, Inc (EDIT) Q3 2021 Earnings Call Transcript
November 08, 2021
EDIT earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Editas Medicine Stock Is Jumping Today
November 08, 2021
The gene-editing biotech company provided its Q3 update.
Via
The Motley Fool
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...
Via
Benzinga
Analyst Ratings For Editas Medicine
October 19, 2021
Within the last quarter, Editas Medicine (NASDAQ:EDIT) has observed the fo...
Via
Benzinga
Should You Scoop Up Shares of This Promising Biotech on the Dip?
October 28, 2021
This gene-editing specialist could still be an excellent long-term play.
Via
The Motley Fool
The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO
October 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Committee Recommends Approval Of Merck, Pfizer's Pneumococcal Vaccine...
Via
Benzinga
Exposures
Product Safety
Editas Medicine Could Skyrocket if Its Gene Editing Therapy Proves Successful
October 19, 2021
EDIT stock has been on a roller coaster this year, but it may be at an appealing price for speculative buyers who believe in its CRISPR tech.
Via
InvestorPlace
What's Hot in the Stock Market?
October 11, 2021
We've got a look at Merck and Amazon and Warby Parker and more.
Via
The Motley Fool
Exposures
COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
October 19, 2021
Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ:
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
October 08, 2021
Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 74.6...
Via
Benzinga
3 Spooky Healthcare Stocks I Would Avoid in October
October 07, 2021
Investors craving treats should look elsewhere this month.
Via
The Motley Fool
Editas Stock Firestorm Rages On; CRISPR Gene-Editing Stock Flashes Sell Signal
September 30, 2021
One of the leading CRISPR stock is under pressure on underwhelming data.
Via
Investor's Business Daily
52 Biggest Movers From Yesterday
September 30, 2021
Gainers Paltalk, Inc. (NASDAQ: PALT) shares jumped 60.1% to close at $8.39 on Wednesday. Smart Share Global Limited (NASDAQ: EM) jumped 36.2% to close at $3.91. Smart Share...
Via
Benzinga
EDIT Stock Is Plunging 20%. Here’s the Gene-Editing News Dragging It Down.
September 29, 2021
Today, investors in Editas Medicine and EDIT stock are pricing in some clinical trial results that are being viewed negatively by the market.
Via
InvestorPlace
PreMarket Prep Stock Of The Day: Editas Medicine
September 29, 2021
Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
September 29, 2021
Gainers NuCana (NASDAQ:NCNA) stock increased by 22.36% to $2.9 during Wednesday's regular session. The current volume of 77.9 million shares is 21650.59% of NuCana...
Via
Benzinga
Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder Candidate
September 29, 2021
Editas Medicine Inc (NASDAQ: EDIT) has announced initial clinical data from the ongoing Phase 1/2 BRILLIANCE trial of EDIT-101 for blindness due to Leber...
Via
Benzinga
Why Shares of Editas Medicine Are Lower This Morning
September 29, 2021
Incomplete data is disappointing investors after a long wait.
Via
The Motley Fool
Editas Medicine Stock Plunges As CRISPR Gene-Editing Drug Fails To Impress
September 29, 2021
Editas is working on a treatment for a blindness-causing genetic disorder.
Via
Investor's Business Daily
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
September 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...
Via
Benzinga
Exposures
Product Safety
Biotech Playbook Revisited As Technicals Weaken
September 27, 2021
Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still...
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021
September 24, 2021
Upgrades Berenberg upgraded the previous rating for Tenable Holdings Inc (NASDAQ:
Via
Benzinga
'Fast Money Halftime Report' Picks For September 13
September 13, 2021
On CNBC's "Fast Money Halftime Report," Shannon Saccocia said Stryker Corporation (NYSE: SYK) has had a really nice run since last year. She sees more upside...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 10, 2021
September 10, 2021
Upgrades According to JonesTrading, the prior rating for Orchid Island Capital Inc (NYSE:
Via
Benzinga
10 Biggest Price Target Changes For Friday
September 10, 2021
Wells Fargo lowered the price target on General Motors Company (NYSE:
Via
Benzinga
3 Red-Hot Healthcare Stocks to Buy in September
September 09, 2021
These businesses are firing on all cylinders.
Via
The Motley Fool
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
September 03, 2021
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.
Via
InvestorPlace
60 Biggest Movers From Yesterday
August 24, 2021
Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share,...
Via
Benzinga
Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today
August 23, 2021
Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology.
Via
InvestorPlace
35 Stocks Moving In Monday's Mid-Day Session
August 23, 2021
Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares climbed 187.8% to $17.53 after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value...
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.